CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX) Files An 8-K Other Events
Item 8.01. Other Events.
On May 28, 2019, Cytori Therapeutics, Inc. (the “Company”) adjourned its 2019 Annual Meeting of Stockholders (the “Annual Meeting”) before any of the proposals set forth in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 19, 2019 (the “Proxy Statement”), were voted upon. In announcing the adjournment of the Annual Meeting, the chairman of the meeting announced that the Annual Meeting will reconvene on June 18, 2019 at 9:00 a.m., Pacific Time, at 3020 Callan Road, San Diego, California 92121, the Company’s headquarters. The Company does not expect any items of business at the re-convened Annual Meeting other than those set forth in the Proxy Statement.
A copy of the press release announcing the adjournment of the Annual Meeting is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
The following exhibits are furnished as part of this Current Report on Form 8-K:
(d) Exhibits.
99.1Press Release, dated May 30, 2019.
CYTORI THERAPEUTICS, INC. Exhibit
EX-99.1 2 cytx-ex991_6.htm EX-99.1 cytx-ex991_6.htm Exhibit 99.1 Cytori Announces New Annual Stockholders Meeting Date for June 18 May 28 Meeting Adjourned to Provide Additional Time to Obtain Approval of Key Business SAN DIEGO,…
To view the full exhibit click here
About CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX)
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.